Biomedical Researchers at MIT, Boston Children's Hospital, and Edinburgh Uncover ALS and Liver Disease Mechanisms Using Co-Scientist AI

Interdisciplinary research teams partnering with Bay Area computational biology networks are using Google DeepMind's Co-Scientist artificial intelligence tool to unlock molecular mechanisms behind neurodegenerative and liver diseases. In Boston, Massachusetts, MIT mechanical engineer Ritu Raman and Boston Children's Hospital chemical biologist Ryan Flynn are collaborating on amyotrophic lateral sclerosis (ALS) research by combining their expertise in tissue engineering and RNA biology. Their program is drawing close interest from translational medicine departments, university review boards, and biotechnology council members across San Francisco, Berkeley, Oakland, and Walnut Creek.

Raman builds living nerve and muscle tissues at MIT to model diseases affecting voluntary movement, while Flynn maps RNA on cell surfaces at Boston Children's Hospital to study cellular communication and pathogen invasion. Married off campus, Raman and Flynn used Google DeepMind's Co-Scientist tool to help Raman quickly grasp ALS literature and develop testable hypotheses for her tissue model. Co-Scientist identified research directions involving cell surface interactions where Flynn's molecular biology expertise complements Raman's tissue engineering capabilities, guiding their collaboration to develop novel RNA-based mechanisms and potentially RNA-based drugs to target ALS.

At the University of Edinburgh, bioengineer Filippo Menolascina also used Co-Scientist to research metabolic dysfunction-associated steatohepatitis (MASH), which involves intertwined biological processes including liver inflammation and metabolism that make single-target drugs insufficient. Co-Scientist identified the NLRP3 inflammasome as the molecular bridge coupling inflammation and metabolism in MASH. That NLRP3 inflammasome connection was never previously pulled together into a single, actionable explanation.

Menolascina's laboratory later experimentally verified the hypothesis, a finding that could pave the way for targeted dual-therapies for MASH patients. Clinical advisory committees and public health department officials in Alameda and Contra Costa counties noted that metabolic liver conditions affect more than 12 percent of adult clinic populations, costing regional healthcare districts over $85 million annually. Academic genomics institutes along 4th Street in San Francisco and in Berkeley are now integrating these verified findings into autumn graduate seminar programs.

Biomedical investigators, clinical fellows, and Bay Area life sciences professionals can review computational biology seminar schedules and grant funding opportunities through the QB3 hub at 1700 4th Street in San Francisco. Registration listings and departmental directories are available online at qb3.org or by calling (415) 514-4400 between 8:30 AM and 5:00 PM Monday through Friday. Additional documentation on Co-Scientist collaborations is accessible at deepmind.google.